DNA OncoNex is a revolutionary Next Generation Sequencing (NGS) test that sheds light on the genetic foundation of thyroid cancer in the field of oncology diagnostics. This thorough examination explores the molecular causes of thyroid cancers in great detail, providing important information about genetic abnormalities and possible treatment targets.
Targeted NGS technology is used by the DNA OncoNex (THYROID CANCER) Test to examine genes linked to thyroid cancer, including tumors of the esophagus, lung, thyroid, and head and neck. This assay provides a comprehensive genetic profile of the malignancy by closely examining the genetic mutations and changes present in thyroid carcinoma cells.
This sophisticated test detects a range of genetic abnormalities in thyroid cancer cells, including amplifications, rearrangements, deletions, and mutations in particular cancer-related genes. The DNA OncoNex test makes accurate tumor genetic characterisation possible by clarifying these molecular signals.
Empowering Thyroid Cancer Management
In conclusion, the DNA OncoNex (THYROID CANCER) Test, which uses cutting-edge NGS technology to clarify the genetic makeup of tumors, is a revolutionary approach to thyroid cancer diagnoses. Through the process of deciphering the molecular nuances of thyroid cancer, this test provides oncologists with useful genetic data for precision therapy, which in turn improves patient outcomes and treatment.
By using DNA OncoNex to explore the genetic landscape, people managing their thyroid health can discover new possibilities for customized cancer management. Accept the future of focused genetic insights in oncology diagnostics, which open the door to more individualized treatment plans and better results.
Clinical utility:
Identify Driver Mutations - mutation in the DNA Sequence that cause cells to become cancers , grow & spread in body
Drug profiling for Chemotherapy & Targeted Drugs
Predictive genomic biomarker identification to guide the therapeutic process
The targeted NGS panel offers wide coverage and in-depth analysis to detect the known and novel variants
The multigene approach reduces the time for diagnosis providing a more economical solution
MapmyGenome Offerings
Major emphasis on >100 cancer genes associated with each cancer panel
Screening for clinically significant genes based on National Comprehensive Cancer Network (NCCN) guidelines.
Genetic counselling to guide through the report and discuss the available management & treatment options in case of clinical findings
Reporting - Pathogenic and Likely Pathogenic Variants are reported following the ACMG recommended guidelines.
Best in class Bioinformatics pipeline for the most accurate analysis by our experienced Bioinformatics team.
Report
Report generation with quick TAT
99?curacy
Fast Therapeutic Benefits
Easy to read & self-explanatory report
